In light of these considerations, the present study aims to investigate the potential of US-based radiomics, utilizing both intratumoral and peritumoral regions, in establishing an interpretable ML model for predicting Ki-67 expression in BC patients, thereby contributing to individualized treatment strategies and prognosis assessments. This evidence concerns the gene MKI67 and breast cancer.